Jason Gerberry, an analyst from Bank of America Securities, reiterated the Buy rating on Bluebird Bio (BLUE – Research Report). The associated pric...
The primary driver behind the positive stance is the proposed acquisition of RayzeBio, which significantly bolsters BMY’s oncology pipeline by adding radiopharmaceutical therapeutics for the treatment of solid tumors. This move is seen as a diversification strategy that could potentially...
Treatment of Upper and Lower Gastrointestinal Malignancies: Current Advances and Future ProspectsDiagnosis for SARS-CoV-2 InfectionsDiagnostic and Therapeutic Challenges in Oral MedicineEpidemiology and Control of MalariaEpidemiology of Noncommunicable DiseasesEpigenetics and DiseaseEpigenetics and Disease II...